Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EEF1A1
REST API REST API
Homo sapiens
EEF1A1 is differentially expressed in 262 experiments: 140 organism parts: cerebellum, heart, ... (138 more);, 170 disease states: normal, acute myeloid leukemia, ... (168 more);, 85 cell types 316 cell lines 36 compound treatments and 72 other conditions.
Synonyms EEF1A, LENG7, EE1A1, EF1A
Orthologs EF1A_CHICK (Gallus gallus)   EEF1A1 (1 of 2) (Danio rerio)   TEF2 (Saccharomyces cerevisiae)   Eef1a1 (Mus musculus)   TEF1 (Saccharomyces cerevisiae)   eef1a1 (Danio rerio)   F1M6C2_RAT (Rattus norvegicus)   ENSBTAG00000035926 (Bos taurus)   ENSBTAG00000046034 (Bos taurus)   eef1a1 (Xenopus laevis)   EEF1A1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, eukaryotic translation elongation factor 1 complex, GTPase activity, protein binding, cytoplasm, translation elongation factor activity, translational elongation, cellular protein metabolic process, translation, GTP binding, nucleotide binding, gene expression
InterPro Term Transl_elong_EFTu/EF1A_2, Transl_elong_EFTu/EF1A_C, Transl_elong_EF1A_euk/arc, ProtSyn_GTP-bd
UniProt Accession A6PW80, Q96EB3, Q6IPS9, Q6IQ15, P68104, Q504Z0, Q5VTE0, Q2F837, Q6P4C9, Q8IUB0, Q5JR01, Q96C29, E7EPH7, F8W6I0
Search EB-eye ENSG00000156508
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (31 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
C7H2-R19E7
1
E-GEOD-22152
310 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (46 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
T-ALL
1
E-GEOD-19069
CD16+ dendritic cell
1
E-TABM-34
SVG-A
1
E-GEOD-7819
79 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (59 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-16363, E-GEOD-21912, E-GEOD-8121
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
melanoma
2
E-MTAB-37, E-MTAB-62
164 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, ... (25 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
control - IL-1b
1
E-GEOD-7216
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
chloroguine
1
E-GEOD-5418
N-nitrosodimethylamine
1
E-GEOD-6907
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-43, E-TABM-868, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43

Vehicle
studied in E-GEOD-5258

Processing time: 0.457 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM